<code id='E05557F440'></code><style id='E05557F440'></style>
    • <acronym id='E05557F440'></acronym>
      <center id='E05557F440'><center id='E05557F440'><tfoot id='E05557F440'></tfoot></center><abbr id='E05557F440'><dir id='E05557F440'><tfoot id='E05557F440'></tfoot><noframes id='E05557F440'>

    • <optgroup id='E05557F440'><strike id='E05557F440'><sup id='E05557F440'></sup></strike><code id='E05557F440'></code></optgroup>
        1. <b id='E05557F440'><label id='E05557F440'><select id='E05557F440'><dt id='E05557F440'><span id='E05557F440'></span></dt></select></label></b><u id='E05557F440'></u>
          <i id='E05557F440'><strike id='E05557F440'><tt id='E05557F440'><pre id='E05557F440'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:fashion    Page View:4
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In